Bullock Wealth Management’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$34.1K Hold
907
– – 0.01% 318
2026
Q2
$39.4K Hold
907
– – 0.02% 304
2026
Q1
$18.7K Sell
907
-287
-24% -$4.87K 0.01% 351
2025
Q4
$16K Hold
1,194
– – 0.01% 361
2025
Q3
$14.7K Hold
1,194
– – 0.01% 375
2025
Q2
$7.98K Hold
1,194
– – ﹤0.01% 421
2025
Q1
$6.62K Hold
1,194
– – ﹤0.01% 426
2024
Q4
$8.31K Hold
1,194
– – ﹤0.01% 411
2024
Q3
$6.72K Hold
1,194
– – ﹤0.01% 413
2024
Q2
$8.44K Buy
+1,194
New +$10.4K 0.01% 370
2021
Q4
– Sell
-2
Closed -$59 – 512
2021
Q3
$59 Buy
+2
New +$86 ﹤0.01% 493

Other funds holding DFTX

Bullock Wealth Management's DFTX Position: Q3 2026 in Review

Bullock Wealth Management held its Definium Therapeutics (DFTX) position steady in Q3 2026 at 907 shares worth $34.1K. The position accounts for 0.01% of the portfolio, ranked #318.

Bullock Wealth Management first reported a position in DFTX in Q3 2021 and has held it in 11 quarters since. The position peaked at $39.4K in Q2 2026. 354 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Bullock Wealth Management held 907 shares of Definium Therapeutics worth $34.1K as of Q3 2026.
  • Bullock Wealth Management left its Definium Therapeutics share count unchanged in Q3 2026.
  • Definium Therapeutics made up 0.01% of Bullock Wealth Management's portfolio in Q3 2026, its #318 holding.
  • Bullock Wealth Management first reported a position in Definium Therapeutics in Q3 2021 and has held it in 11 quarters since.
  • Bullock Wealth Management's Definium Therapeutics position peaked at $39.4K in Q2 2026.
  • 354 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Bullock Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.